Boehringer has strengthened its position in the cardiology sector with the launch of Benefortin, an ACE inhibitor licensed for the treatment of congestive heart failure in dogs and chronic renal insufficiency in cats.
Boehringer Ingelheim Vetmedica has strengthened its position in the cardiology sector with the launch of Benefortin, an ACE inhibitor licensed for the treatment of congestive heart failure (CHF) in dogs.
The new product is also licensed for the treatment of chronic renal insufficiency (CRI) in cats.
Benefortin, which contains benazepril hydrochloride as its active ingredient, uses novel micro-cap technology to mask the taste of the bitter molecule, even if it is bitten, crunched or chewed.
Benefortin is available in:
- 5mg and 20mg tablets for dogs, and
- 2.5mg tablets for dogs and cats.
Boehringer Ingelheim brand manager Jemima Scott said: “The addition of Benefortin to our cardiology portfolio now enables us to provide veterinary practices with two of the cornerstones of canine CHF treatment, and the palatability of Benefortin makes it an excellent choice for vets needing to prescribe an ACE inhibitor.”
To support the launch, Boehringer is offering veterinary practices the opportunity to win one of three Bosch microwave ovens in a prize draw, by answering three multiple choice questions on the ACE inhibitor.
- For further information on Benefortin or the relating promotion, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.